News
The second-largest pharmaceutical company in the UK reveals its second quarter results have declined due to challenging market conditions and loss of product exclusivity. AstraZeneca has revealed its revenue for the second quarter is down by 18% to US $6.7million, but the company says…
GSK announce a 2% decrease in sales in the second-quarter as the global pharma company releases its financial results. With the announcement of its second-quarter financial results, global pharmaceutical company, GlaxoSmithKline, has warned…
FDA reviewers have revealed, ahead of external voting for approval, that Roche’s eye drug, Lucentis, may be able to treat vision loss in diabetes, known as DME. Lucentis, made by Roche unit Genentech, is currently waiting for approval from the US FDA for expanded use, as the global…
Joint statement is released from the IFPMA, PhRMA, EFPIA and JPMA as they combine forces to tackle counterfeit medicines. Four major pharmaceutical associations issue a joint policy statement to tackle counterfeit medicines from sources such as Internet pharmacies…
Global biopharmaceutical company, Bristol-Myers Squibb, has revealed that its advanced liver cancer pill, brivanib, failed its second late-stage clinical trial. Bristol-Myers Squibb is considering whether or not to continue developing its advanced liver cancer pill…
Novartis’ Afinitor, for treatment in combination with Aromasin, for patients with certain advanced breast cancers, has been approved by the US FDA. The US FDA has approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain…
J&J’s second-quarter financial results initiate debate amongst analysts as to what the future of the US healthcare giant holds. Johnson & Johnson has announced its second-quarter 2012 financial results – and it does not look…
Late-stage clinical trial of Alzheimer’s drug fails to slow disease. A drug developed by Pfizer, Johnson & Johnson and Elan Corp. to treat Alzheimer’s failed to slow the disease in a late-stage trial…
Sanofi and Regeneron announce the launch of their phase 3 clinical program, ODYSSEY, for the evaluation of SAR236553/REGN727, a potential PCSK9 inhibitor. Sanofi and Regeneron Pharmaceuticals, Inc. have announced that several clinical trials have initiated patient enrolment…
